請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46329
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳水田(Shui-Tein Chen) | |
dc.contributor.author | Ting-Chia Lin | en |
dc.contributor.author | 林庭加 | zh_TW |
dc.date.accessioned | 2021-06-15T05:03:52Z | - |
dc.date.available | 2016-07-26 | |
dc.date.copyright | 2010-07-29 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-07-27 | |
dc.identifier.citation | 1. Bataller, R. and D.A. Brenner, Liver fibrosis. J Clin Invest, 2005. 115(2): p. 209-18.
2. Hu, Q.W. and G.T. Liu, Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action. Life Sci, 2006. 79(6): p. 606-12. 3. Schluger, L.K., et al., Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology, 1996. 23(5): p. 971-6. 4. Bonnard, P., et al., Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat, 2007. 14(11): p. 806-11. 5. Jezequel, A.M., et al., Dimethylnitrosamine-induced cirrhosis. Evidence for an immunological mechanism. J Hepatol, 1989. 8(1): p. 42-52. 6. George, J., et al., Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. Toxicology, 2001. 156(2-3): p. 129-38. 7. Consolo, M., et al., Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med, 2009. 24(2): p. 143-52. 8. Strey, C.W., et al., The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med, 2003. 198(6): p. 913-23. 9. Jeong, W.I. and B. Gao, Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol, 2008. 23 Suppl 1: p. S112-8. 10. Knittel, T., et al., Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol, 2000. 113(6): p. 443-53. 11. Taub, R., Liver regeneration 4: transcriptional control of liver regeneration. FASEB J, 1996. 10(4): p. 413-27. 12. Zhou, K. and L.G. Lu, Assessment of fibrosis in chronic liver diseases. J Dig Dis, 2009. 10(1): p. 7-14. 13. Wynn, T.A., Cellular and molecular mechanisms of fibrosis. J Pathol, 2008. 214(2): p. 199-210. 14. Huang, H., et al., A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology, 2007. 46(2): p. 297-306. 15. Haggerty, H.G. and M.P. Holsapple, Role of metabolism in dimethylnitrosamine-induced immunosuppression: a review. Toxicology, 1990. 63(1): p. 1-23. 16. Anderson, L.M., et al., Reduced blood clearance and increased urinary excretion of N-nitrosodimethylamine in patas monkeys exposed to ethanol or isopropyl alcohol. Cancer Res, 1992. 52(6): p. 1463-8. 17. Yang, C.S., et al., Deuterium isotope effect in the interaction of N-nitrosodimethylamine, ethanol, and related compounds with cytochrome P-450IIE1. Chem Res Toxicol, 1991. 4(4): p. 408-13. 18. Ala-Kokko, L., et al., Gene expression of type I, III and IV collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J, 1987. 244(1): p. 75-9. 19. Risteli, J. and K.I. Kivirikko, Intracellular enzymes of collagen biosynthesis in rat liver as a function of age and in hepatic injury induced by dimethylnitrosamine. Changes in prolyl hydroxylase, lysyl hydroxylase, collagen galactosyltransferase and collagen glucosyltransferase activities. Biochem J, 1976. 158(2): p. 361-7. 20. Wasser, S. and C.E. Tan, Experimental models of hepatic fibrosis in the rat. Ann Acad Med Singapore, 1999. 28(1): p. 109-11. 21. Jezequel, A.M., et al., Modulation of extracellular matrix components during dimethylnitrosamine-induced cirrhosis. J Hepatol, 1990. 11(2): p. 206-14. 22. Tanaka, H., et al., Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine. Clin Exp Med, 2009. 9(3): p. 229-33. 23. Muroski, M.E., et al., Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol, 2008. 9(1): p. 34-46. 24. Sasaki, M., et al., Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha. Mediators Inflamm, 2000. 9(3-4): p. 155-60. 25. Morgia, G., et al., Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res, 2005. 33(1): p. 44-50. 26. Iredale, J.P., Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol, 1997. 29(1): p. 43-54. 27. Herbst, H., et al., Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol, 1997. 150(5): p. 1647-59. 28. Benyon, R.C., et al., Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology, 1996. 110(3): p. 821-31. 29. Iredale, J.P., et al., Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond), 1995. 89(1): p. 75-81. 30. Knittel, T., et al., Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol, 1999. 30(1): p. 48-60. 31. Kolaczkowska, E., et al., Resident peritoneal leukocytes are important sources of MMP-9 during zymosan peritonitis: superior contribution of macrophages over mast cells. Immunol Lett, 2007. 113(2): p. 99-106. 32. Iyer, S., et al., Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. J Biol Chem, 2007. 282(1): p. 364-71. 33. Hamze, A.B., et al., Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. Protein Sci, 2007. 16(9): p. 1905-13. 34. Will, H., et al., The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem, 1996. 271(29): p. 17119-23. 35. Salguero Palacios, R., et al., Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest, 2008. 88(11): p. 1192-203. 36. McCrudden, R. and J.P. Iredale, Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol, 2000. 15(4): p. 1159-68. 37. Tsai, Y.Y., et al., Effect of TIMP-1 and MMP in pterygium invasion. Invest Ophthalmol Vis Sci, 2010. 51(7): p. 3462-7. 38. Kisseleva, T. and D.A. Brenner, Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol, 2006. 21 Suppl 3: p. S84-7. 39. Hemmann, S., et al., Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol, 2007. 46(5): p. 955-75. 40. Perez-Tamayo, R., Cirrhosis of the liver: a reversible disease? Pathol Annu, 1979. 14 Pt 2: p. 183-213. 41. Wakim-Fleming, J. and K.D. Mullen, Long-term management of alcoholic liver disease. Clin Liver Dis, 2005. 9(1): p. 135-49. 42. Kral, J.G., et al., Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery, 2004. 135(1): p. 48-58. 43. Dufour, J.F., R. DeLellis, and M.M. Kaplan, Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med, 1997. 127(11): p. 981-5. 44. Hammel, P., et al., Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med, 2001. 344(6): p. 418-23. 45. Muretto, P., E. Angelucci, and G. Lucarelli, Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med, 2002. 136(9): p. 667-72. 46. Kral, J.G., et al., Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery, 2004. 135(1): p. 48-58. 47. Dixon, J.B., et al., Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology, 2004. 39(6): p. 1647-54. 48. Kweon, Y.O., et al., Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol, 2001. 35(6): p. 749-55. 49. Poynard, T., P. Bedossa, and P. Opolon, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997. 349(9055): p. 825-32. 50. Lok, A.S., et al., Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology, 2005. 42(2): p. 282-92. 51. Adams, L.A., et al., Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem, 2005. 51(10): p. 1867-73. 52. Cales, P., et al., A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 2005. 42(6): p. 1373-81. 53. Kelleher, T.B., et al., Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol, 2005. 43(1): p. 78-84. 54. Sakugawa, H., et al., Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol, 2005. 11(2): p. 255-9. 55. Hui, A.Y., et al., Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol, 2005. 100(3): p. 616-23. 56. Zeng, M.D., et al., Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology, 2005. 42(6): p. 1437-45. 57. Arthur, M.J., Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology, 2002. 122(5): p. 1525-8. 58. Strey, C.W., et al., The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med, 2003. 198(6): p. 913-23. 59. Yong, V.W., et al., Matrix metalloproteinases and diseases of the CNS. Trends Neurosci, 1998. 21(2): p. 75-80. 60. Stetler-Stevenson, W.G., Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol, 1996. 148(5): p. 1345-50. 61. Consolo, M., et al., Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med, 2009. 24(2): p. 143-52. 62. Kim, T.H., et al., Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology, 2000. 31(1): p. 75-82. 63. Buchanan, G.R., C.A. Holtkamp, and A. Johnson, Reduced serum haptoglobin values in hemophiliacs receiving monoclonally purified factor VIII concentrates. Am J Hematol, 1990. 33(4): p. 234-7. 64. Heinrich, P.C., J.V. Castell, and T. Andus, Interleukin-6 and the acute phase response. Biochem J, 1990. 265(3): p. 621-36. 65. Desilets, A., et al., Inhibition by deacetylase inhibitors of IL-1-dependent induction of haptoglobin involves CCAAT/Enhancer-binding protein isoforms in intestinal epithelial cells. Biochem Biophys Res Commun, 2000. 276(2): p. 673-9. 66. Jacob, H.S., Newly recognized causes of atherosclerosis: the role of microorganisms and of vascular iron overload. J Lab Clin Med, 1994. 123(6): p. 808-16. 67. Marinkovic, S. and H. Baumann, Structure, hormonal regulation, and identification of the interleukin-6- and dexamethasone-responsive element of the rat haptoglobin gene. Mol Cell Biol, 1990. 10(4): p. 1573-83. 68. Parola, M. and G. Robino, Oxidative stress-related molecules and liver fibrosis. J Hepatol, 2001. 35(2): p. 297-306. 69. Feldstein, A.E., et al., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology, 2009. 50(4): p. 1072-8. 70. Leroy, V., et al., Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol, 2004. 99(2): p. 271-9. 71. El-Gindy, I., et al., Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol, 2003. 10(1): p. 27-35. 72. Lichtinghagen, R., et al., Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem, 2000. 46(2): p. 183-92. 73. Will, H., et al., The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem, 1996. 271(29): p. 17119-23. 74. Olszynski, K. and M. Zimowska, [Structure and function of matrix metalloproteinases]. Postepy Biochem, 2009. 55(1): p. 76-84. 75. McCrudden, R. and J.P. Iredale, Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol, 2000. 15(4): p. 1159-68. 76. Park, S.Y., et al., Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury. J Korean Med Sci, 2010. 25(4): p. 570-6. 77. Guo, J. and S.L. Friedman, Hepatic fibrogenesis. Semin Liver Dis, 2007. 27(4): p. 413-26. 78. Iredale, J.P., et al., Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology, 1996. 24(1): p. 176-84. 79. Iredale, J.P., et al., Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 1998. 102(3): p. 538-49. 80. Kossakowska, A.E., et al., Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol, 1998. 153(6): p. 1895-902. 81. Markiewski, M.M., et al., C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol, 2004. 173(2): p. 747-54. 82. He, S., et al., A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest, 2009. 119(8): p. 2304-16. 83. Strey, C.W., et al., The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med, 2003. 198(6): p. 913-23. 84. Mastellos, D., et al., A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol, 2001. 166(4): p. 2479-86. 85. Fausto, N., J.S. Campbell, and K.J. Riehle, Liver regeneration. Hepatology, 2006. 43(2 Suppl 1): p. S45-53. 86. Guicciardi, M.E. and G.J. Gores, Apoptosis: a mechanism of acute and chronic liver injury. Gut, 2005. 54(7): p. 1024-33. 87. Friedman, S.L., Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 2000. 275(4): p. 2247-50. 88. Yin, M., et al., Lack of apoE causes alteration of cytokines expression in young mice liver. Mol Biol Rep, 2010. 37(4): p. 2049-54. 89. Ferre, N., et al., Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol, 2009. 296(3): p. G553-62. 90. Reardon, C.A., et al., Processing of rat liver apoprotein E primary translation product. J Lipid Res, 1984. 25(4): p. 348-60. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46329 | - |
dc.description.abstract | 此篇論文的研究目的在於探討可逆性肝臟纖維化和不可逆性肝臟纖維化在大鼠血清中蛋白質的變化,藉此剖析初期肝臟纖維化在可逆性與不可逆性之分水嶺時,調控肝臟纖維化選擇日後發展路徑的可能機制。本篇論文中,利用致癌劑 dimethylnitrosamine (DMN) 誘導大鼠產生肝臟纖維化,在纖維化不同程度以及休息不同週數的個別時期,經過肝臟切片、免疫染色確定纖維化程度,並定義肝臟纖維化可逆與不可逆的時間點。抽取肝臟纖維化不同時期的大鼠血清進行蛋白質體分析;藉由二維電泳 (Two Dimensional Electrophoresis)、膠體內水解(In gel digestion)、質譜分析,並利用PDQUEST 分析軟體,鑑定出有差異的蛋白質,其中包括血紅素結合蛋白 (haptoglobin),脂蛋白E (Apolipoprotein E)及補體蛋白C3 (Complement C3)等蛋白質。依據鑑定出表現量有差異的蛋白質,透過生物資訊軟體MetacoreTM, 分析在統計上有顯著意義的網絡 (Network),發現Alternative complement pathway是參與調控肝臟纖維化,選擇可逆與不可逆性路徑的可能機制。補體蛋白C3被視為是調控肝細胞增殖的重要因子,但目前文獻並沒有提到補體蛋白C3與肝臟纖維化可逆性的關係。本研究的重要結果在於,由MetacoreTM分析的網絡中發現,基質金屬蛋白酵素2,9及基質金屬蛋白酵素抑制物1,2,參與由補體蛋白C3所調控的網絡,而基質金屬蛋白酵素及基質金屬蛋白酵素抑制物是影響肝臟纖維化重要的酵素。因此,研究結果顯示,補體蛋白C3可能扮演調控可逆性與不可逆性肝臟纖維化的重要角色。 | zh_TW |
dc.description.abstract | The aim of study is to compare protein expression profile between reversible and irreversible liver fibrosis in DMN-induced rat model and find out the pivotal pathway regulating the development of liver fibrosis. In this study, DMN (Dimethylnitrosamine), carcinogen, was used to induce liver fibrosis in rat. The degree of liver fibrosis was determined by histological analysis of liver sections. Immunohistochemistry stain of liver sections was performed in different liver fibrosis stages for timing definition of reversible and irreversible liver fibrosis in the DMN-induced rat model. Collecting the rat serum in different stages of fibrosis followed by proteomic analysis, which included 2DE (two-dimensional electrophoresis)、In-gel digestion and matrix-assisted laser desorption/ionization mass spectrometry. The differentially expressed protein spots were analyzed by computer-assisted image analysis (PDQEST) software (p<0.05). Identified proteins included Hp (haptoglobin), ApoE (apolipoprotein E) and complement C3. Based on the identified proteins, MetacoreTM was applied to organize network relevant to the identified proteins. The bioinformatics tool-based analyzed result shows Alternative complement pathway might be associated with the reversible regulation of liver fibrosis. Complement C3 is regard as a pivotal factor regulating the proliferation of hepatocyte. The result indicated complement C3 might be an of importance factor regulating the development of liver fibrosis, up to now, no studies elucidate the role of complement C3 in the reversibility of liver fibrosis. We also found MMPs and TIMPs involved in complement C3 regulated pathway. The functional role of MMPs and TIMPs in liver fibrosis was studied in a number of previous researches, but detail still not completely understood. Taken together, complement C3 might serve as a notable mediator involved in reversibility of liver fibrosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T05:03:52Z (GMT). No. of bitstreams: 1 ntu-99-R97b46029-1.pdf: 3499291 bytes, checksum: 6cd1303c176153c8c53ea9f070e21921 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | Content
中文摘要 ii Abstract iii Abbreviation viii List of figures ix List of tables x 1. Introduction 1 1.1. Introduction of live structure and features 1 1.2. Liver fibrosis and cirrhosis 2 1.3. Innate immunity and liver fibrosis (complement system) 3 1.4. Diagnosis tools of fibrosis in chronic liver diseases 5 1.5. Biomarker of liver fibrosis 5 1.6. DMN-induced liver fibrosis in rat 6 1.7. Roles of MMPs and TIMPs in liver fibrosis 7 1.8. Reversal of liver fibrosis 8 1.9. Current medical therapies of fibrosis or cirrhosis 10 1.10. Reversibility of DMN-induced liver fibrosis in rat 11 2. Materials and Methods 12 2.1. Electrophoresis, scanning and image analysis 12 2.2. Analysis of protein expression 13 2.3. Enzymatic In-Gel Digestion 13 2.4. Peptide mapping by mass spectra analysis 14 2.5. Enzyme-linked immunosorbent assay (ELISA) of Complement C3 15 2.6. Western blot assay 15 2.7. Gel band visualization and quantification 16 2.8. Statistical analysis of western blotting data 16 2.9. Bioinformatics analysis 17 3. Results 18 3.1. Analysis of protein expression in DMN-induced fibrosis model 18 3.2. Comparison of differentially expressed proteins by PDQUEST 18 3.3. Identification of differentially expressed proteins 19 3.4. Validation of differentially expressed proteins by western blot analysis 19 3.5. Expression levels of MMPs and TIMPs 20 3.6. Relationship between complement C3 and hepatocyte apoptosis 20 3.7. Network prediction by bioinformatics tool 21 4. Discussion 22 4.1. Expression level of Haptoglobin in DMN-induced liver fibrosis 22 4.2. Diversified expressions of MMPs and TIMPs in liver fibrosis 23 4.3. Roles of complement component 3 in reversal of liver fibrosis 26 4.4. Various ApoE protein pattern in DMN-induced liver fibrosis rat model 27 5. Conclusion 29 6. References 31 7. Figures 44 8. Tables 60 | |
dc.language.iso | en | |
dc.title | 從DMN誘導肝臟纖維化的大鼠動物模型中尋找生物標記並探討肝臟纖維化的可逆機制 | zh_TW |
dc.title | Potential biomarker discovery revealing the mechanism of reversal in the DMN-induced rat reversible liver fibrosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳世雄(Shih-Hsiung Wu),阮雪芬(Hsueh-Fen Juan),潘台龍(Tai-Long Pan) | |
dc.subject.keyword | DMN誘導的大鼠肝臟纖維化,二維電泳,免疫組織染色,補體蛋白C3,基質金屬蛋白酵素,基質金屬蛋白酵素抑制物,肝細胞增殖, | zh_TW |
dc.subject.keyword | DMN-induced rat liver fibrosis,2-DE,immunohistochemistry stain,complement component 3,MMPs,TIMPs,hepatocyte proliferation, | en |
dc.relation.page | 62 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-07-28 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 3.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。